Monographs: Dosage forms: Specific monographs: Clindamycin palmitate powder for oral solution (Clindamycin palmitas pulvis pro solutione perorali)2020-01
Category. Antibacterial. Storage. Clindamycin palmitate powder for oral solution should be kept in a tightly closed container. Additional information. Strength in the current WHO Model List of Essential Medicines (EML): 75 mg/5 mL clindamycin (as palmitate). Strengths in the current WHO EML for Children: 75 mg/5 mL clindamycin (as palmitate). Clindamycin palmitate powder for oral solution may contain excipients that are suspended in the reconstituted solution. Shake until the solution is uniform. Labelling. The designation on the container of clindamycin palmitate powder for oral solution should state that the active ingredient is clindamycin palmitate hydrochloride and the quantity should be indicated in terms of equivalent amount of clindamycin. Requirements Complies with the monograph for Liquid preparations for oral use; the powder complies with the section of the monograph entitled "Powders for oral solutions, oral suspensions and oral drops". Definition. Clindamycin palmitate powder for oral solution is a solution of Clindamycin palmitate hydrochloride in a suitable vehicle, which may be flavoured. It is prepared from the powder as stated on the label before use. When freshly constituted the oral solution contains not less than 90.0% and not more than 110.0% of the labelled amount of clindamycin (C18H33ClN2O5S). Identity test Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography using the conditions given under "Assay". The retention time of the principal peak in the chromatogram obtained with solution (1) corresponds to that of the peak due to clindamycin palmitate in the chromatogram obtained with solution (2). pH value ( 1.13 ). pH of a solution constituted as directed under "Labelling", 2.5–5.0. Loss on drying. Dry the powder for oral solution to constant mass at 60°C under reduced pressure; it loses not more than 30 mg/g. Related substances Use the oral solution immediately after preparation. Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography using a stainless steel column (25 cm × 4.6 mm) packed with particles of silica gel, the surface of which has been modified with chemically-bonded octylsilyl groups (5 μm). Use the following conditions for gradient elution: mobile phase A: ammonium acetate (~0.40 g/L) TS: acetonitrile R (50:50); mobile phase B: acetonitrile R.
Prepare the following solutions in methanol R. For solution (1) transfer a quantity of the oral solution, equivalent to 57 mg of clindamycin to a 10 mL volumetric flask and dilute to volume. For solution (2) dilute 2.0 ml of solution (1) to 100.0 mL. For solution (3) dissolve 75 mg clindamycin palmitate hydrochloride RS (containing clindamycin palmitate hydrochloride and impurity A) and dilute to 10.0 mL. Operate with a flow rate of 1.0 mL per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of 230 nm. Inject alternately 20 μL each of solution (1), (2) and (3). In the chromatogram obtained with solution (3) the retention time of clindamycin palmitate is about 37 minutes. The test is not valid unless the resolution between the peaks due to clindamycin palmitate and impurity A (relative retention about 0.9 with reference to clindamycin palmitate) is at least 3.0. In the chromatogram obtained with solution (1) the following impurities, if present, are eluted at the following relative retentions with reference to clindamycin palmitate: impurity B about 0.8 and impurity A about 0.9. In the chromatogram obtained with solution (1):
Assay. Use the oral solution immediately after preparation. Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography using a stainless steel column (25 cm × 4.6 mm) packed with particles of silica gel, the surface of which has been modified with chemically-bonded octylsilyl groups (5 μm). As the mobile phase, use a mixture of 10 volumes of ammonium acetate (~0,40 g/L) TS and 90 volumes of acetonitrile R. Prepare the following solutions in mobile phase. For solution (1) dilute 2.0 mL of the oral solution to 50.0 mL, filter and use the filtrate. For solution (2) dissolve 50.0 mg clindamycin palmitate hydrochloride RS and dilute to 50.0 mL. Operate with a flow rate of 1.0 mL per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of 230 nm. Inject alternately 20 μL each of solutions (1) and (2) and record the chromatograms for 40 minutes. Measure the areas of the peak responses corresponding to clindamycin palmitate obtained in the chromatograms from solutions (1) and (2). Determine the weight per mL (1.3.1) of the oral solution and calculate the percentage content of clindamycin (C18H33ClN2O5S) in the oral solution, using the declared content of clindamycin palmitate hydrochloride (C34H63ClN2O6S.HCl) in clindamycin palmitate hydrochloride RS. Each mg of clindamycin palmitate hydrochloride (C34H63ClN2O6S.HCl) is equivalent to 0.607 mg clindamycin (C18H33ClN2O5S). Impurities The impurities limited by the requirements of this monograph include those listed in the monograph for Clindamycin palmitate hydrochloride. |